Qing Yi

List of Publications by Year
in descending order

93 papers	5,521 citations	81900 39 h-index	88630 70 g-index
95 all docs	95 docs citations	95 times ranked	7361 citing authors

#	Article	IF	Citations
1	Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 143-156.e5.	16.2	460
2	CD36-mediated ferroptosis dampens intratumoral CD8+ TÂcell effector function and impairs their antitumor ability. Cell Metabolism, 2021, 33, 1001-1012.e5.	16.2	347
3	Th9 cells promote antitumor immune responses in vivo. Journal of Clinical Investigation, 2012, 122, 4160-4171.	8.2	303
4	Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drugâ€“induced apoptosis. Blood, 2009, 114, 3625-3628.	1.4	258
5	Transfection of chimeric antiâ€CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular Oncology, 2014, 8, 297-310.	4.6	215
6	Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages. Cancer Research, 2020, 80, 1438-1450.	0.9	211
7	Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine, 2014, 20, 676-681.	30.7	199
8	Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood, 2010, 116, 210-217.	1.4	192
9	Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complexâ€"Restricted, CD8- and CD4-Specific T-Cell Responses. Blood, 1998, 91, 2459-2466.	1.4	179
10	Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia, 2018, 32, 2250-2262.	7.2	120
11	Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell, 2018, 33, 1048-1060.e7.	16.8	117
12	Tumor-specific IL-9â€“producing CD8⁺Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2265-2270.	7.1	116
13	Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood, 2007, 110, 1587-1594.	1.4	115
14	Human C-Reactive Protein Binds Activating FcÎ³ Receptors and Protects Myeloma Tumor Cells from Apoptosis. Cancer Cell, 2007, 12, 252-265.	16.8	112
15	Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Nature Communications, 2016, 7, 12368.	12.8	103
16	Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood, 2012, 120, 3783-3792.	1.4	100
17	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Journal of Hematology and Oncology, 2018, 11, 58.	17.0	98
18	Cholesterol negatively regulates IL-9â€“producing CD8+ T cell differentiation and antitumor activity. Journal of Experimental Medicine, 2018, 215, 1555-1569.	8.5	98

#	ARTICLE	IF	CITATIONS
19	Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 1998, 47, 131-142.	4.2	92
20	A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood, 2014, 124, 2061-2071.	1.4	87
21	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Science Translational Medicine, 2019, 11, .	12.4	69
22	p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Research, 2012, 72, 6393-6402.	0.9	66
23	Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma. Oncotarget, 2015, 6, 24218-24229.	1.8	66
24	ORP4L is essential for T-cell acute lymphoblastic leukemia cell survival. Nature Communications, 2016, 7, 12702.	12.8	64
25	Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. British Journal of Haematology, 1995, 89, 110-116.	2.5	61
26	Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96. Clinical Cancer Research, 2005, 11, 8808-8815.	7.0	61
27	Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth. Cancer Research, 2008, 68, 8456-8464.	0.9	61
28	Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. British Journal of Haematology, 1997, 96, 338-345.	2.5	57
29	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metabolism, 2021, 33, 78-93.e7.	16.2	57
30	Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nature Communications, 2020, 11, 5902.	12.8	55
31	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Letters, 2015, 356, 443-453.	7.2	52
32	Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. Journal of Molecular Medicine, 2012, 90, 695-706.	3.9	50
33	p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nature Communications, 2014, 5, 4229.	12.8	49
34	B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clinical Cancer Research, 2017, 23, 4212-4223.	7.0	49
35	Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of T _H 9 cells programmed by IL-7. Science Signaling, 2017, 10, .	3.6	47
36	TNF-Î± enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways. , 2019, 7, 28.		47

#	Article	IF	Citations
37	Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2445-2452.	2.5	45
38	p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. International Journal of Cancer, 2015, 136, 34-43.	5.1	45
39	MicroRNAâ€31â€5p enhances the Warburg effect <i>via</i> targeting FIH. FASEB Journal, 2019, 33, 545-556.	0.5	45
40	T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. , 1999, 80, 671-680.		43
41	Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British Journal of Haematology, 1998, 100, 647-654.	2.5	42
42	Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood, 2007, 109, 5455-5462.	1.4	41
43	Multiple myeloma cell-derived IL-32Î³ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Letters, 2019, 446, 38-48.	7.2	39
44	Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. Journal of the National Cancer Institute, 2016, 108, djw131.	6.3	37
45	Human Osteoclasts Are Inducible Immunosuppressive Cells in Response to T cellâ€“Derived IFN-Î³ and CD40 Ligand In Vitro. Journal of Bone and Mineral Research, 2014, 29, 2666-2675.	2.8	36
46	Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 835-845.	4.2	36
47	Oxysterol-binding Protein-related Protein 8 (ORP8) Increases Sensitivity of Hepatocellular Carcinoma Cells to Fas-Mediated Apoptosis. Journal of Biological Chemistry, 2015, 290, 8876-8887.	3.4	36
48	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Research, 2020, 80, 2031-2044.	0.9	36
49	Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells. Frontiers in Immunology, 2018, 9, 1787.	4.8	33
50	MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood, 2020, 136, 2557-2573.	1.4	33
51	IL-9/STAT3/fatty acid oxidationâ€“mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity. Journal of Clinical Investigation, 2022, 132, .	8.2	33
52	Novel Immunotherapies. Cancer Journal (Sudbury, Mass), 2009, 15, 502-510.	2.0	31
53	Myeloma cell lineâ€“derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood, 2009, 114, 3880-3889.	1.4	31
54	USP18 is crucial for IFN-Î³-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Molecular Cancer, 2014, 13, 132.	19.2	31

#	Article	IF	Citations
55	E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs. Journal of Clinical Investigation, 2018, 128, 4821-4831.	8.2	31
56	Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. British Journal of Haematology, 2014, 166, 690-701.	2.5	30
57	C-reactive protein promotes bone destruction in human myeloma through the CD32â€“p38 MAPKâ€“Twist axis. Science Signaling, 2017, 10, .	3.6	28
58	Idiotype-specific T cells in multiple myeloma:Targets for an immunotherapeutic intervention?. Medical Oncology, 1996, 13, 1-7.	2.5	26
59	Anti-Î²2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget, 2015, 6, 8567-8578.	1.8	26
60	Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells. Cancer Cell, 2021, 39, 1610-1622.e9.	16.8	25
61	Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica, 2018, 103, 1369-1379.	3.5	23
62	Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through Î²-catenin signaling pathway. Cancer Biology and Therapy, 2014, 15, 1413-1422.	3.4	22
63	PD-L1â€“Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice. Diabetes, 2015, 64, 529-540.	0.6	21
64	BAFF is involved in macrophage-induced bortezomib resistance in myeloma. Cell Death and Disease, 2017, 8, e3161-e3161.	6.3	18
65	IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. OncoImmunology, 2016, 5, e1237327.	4.6	17
66	BMI1 regulates multiple myeloma-associated macrophageâ€™s pro-myeloma functions. Cell Death and Disease, 2021, 12, 495.	6.3	16
67	Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy. OncoImmunology, 2016, 5, e1238558.	4.6	15
68	Could B7-H4 serve as a target to activate anti-cancer immunity?. International Immunopharmacology, 2016, 38, 97-103.	3.8	15
69	Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy. OncoImmunology, 2014, 3, e28542.	4.6	11
70	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer Letters, 2019, 440-441, 135-144.	7.2	10
71	ALCAM-EGFR interaction regulates myelomagenesis. Blood Advances, 2021, 5, 5269-5282.	5.2	10
72	CD4+ T cells play a crucial role for lenalidomide <i>in vivo</i> anti-tumor activity in murine multiple myeloma. Oncotarget, 2015, 6, 36032-36040.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice. Science Translational Medicine, 2022, 14, eabh2548.	12.4	8
74	PLK1 and Î²-TrCP-Dependent Ubiquitination and Degradation of Rap1GAP Controls Cell Proliferation. PLoS ONE, 2014, 9, e110296.	2.5	7
75	Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma. Haematologica, 2021, 106, 838-846.	3.5	6
76	RARÎ³ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood, 2022, 139, 59-72.	1.4	6
77	Cholesterol induces T cell exhaustion. Aging, 2019, 11, 7334-7335.	3.1	6
78	ALCAM regulates multiple myeloma chemoresistant side population. Cell Death and Disease, 2022, 13, 136.	6.3	6
79	ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1. Blood, 2022, 139, 1052-1065.	1.4	5
80	Current and Future Therapies for Myasthenia Gravis. Drugs and Aging, 1997, 11, 132-139.	2.7	2
81	A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors. Journal of Hematology and Oncology, 2022, 15, 55.	17.0	2
82	The Expression Of CD200 As a Prognostic Factor In Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3082-3082.	1.4	1
83	Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies. Blood, 2019, 134, 5551-5551.	1.4	1
84	Human Muscle Acetylcholine Receptor Reactive T and B Lymphocytes in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1993, 681, 339-341.	3.8	0
85	C-Reactive Protein Binds to FcÎ³RII and Impairs the Differentiation and Function of Dendritic Cells.. Blood, 2006, 108, 1276-1276.	1.4	0
86	Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.. Blood, 2009, 114, 465-465.	1.4	0
87	Triggering of Toll-Like Receptor-4 In Human Multiple Myeloma Cells Promotes Proliferation and Alters Cell Responses to Immune and Chemotherapy Drug Attack. Blood, 2010, 116, 1905-1905.	1.4	0
88	Anti-Î²2 Microglobulin Monoclonal Antibodies Overcome Bortezomib-Induced Drug Resistance In Multiple Myeloma By Inhibition Of Autophagy. Blood, 2013, 122, 929-929.	1.4	0
89	Fibroblast Activation Protein Protects Bortezomib Induced Apoptosis In Multiple Myeloma Cells Through Î²-Catenin Signaling Pathway. Blood, 2013, 122, 3083-3083.	1.4	0
90	Targeting Myeloma-Associated Macrophage Inhibits Multiple Myeloma Progression By Enhancing Anti-Tumor Cytotoxic CD4+ T Cell Response. Blood, 2016, 128, 481-481.	1.4	0

#	Article	IF	Citations
91	AMPK Expressed By Multiple Myeloma Cells Inhibited Metformin-Induced Myeloma Cells Proliferation. Blood, 2016, 128, 5703-5703.	1.4	0
92	Remodeling Ca2+ Flux By ORP4L Is Essential for Leukemia Stem Cells (LSCs) Survival. Blood, 2016, 128, 5257-5257.	1.4	0
93	RAR Gamma Activation Sensitizes Human Myeloma Cells to Carfilzomib Treatment through OAS-RNase L Innate Immune Pathway. Blood, 2020, 136, 36-37.	1.4	0